NCT00167960CompletedNot Applicable
Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.
Wyeth is now a wholly owned subsidiary of Pfizer0 sites1,500 target enrollmentStarted: January 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 1,500
Study Overview
Brief Summary
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients admitted to or transferred to the SICU.
- •Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.
- •Provide written informed consent
Exclusion Criteria
- •Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.
- •Females who are pregnant and breast feeding
- •Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.
- •Those who have already been participating other clinical study related with antibiotics.
Investigators
Similar Trials
Completed
Not Applicable
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive CareEscherichia Coli InfectionsKlebsiella InfectionsNCT00167986Wyeth is now a wholly owned subsidiary of Pfizer480
Completed
Not Applicable
In Vitro Activity of Ceftolozane-tazobactam Against Contemporary Nosocomial Gram "-" Pathogens Isolated in RussiaNosocomial InfectionNCT04679610The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)700
Completed
Phase 4
The Vienna Prograf and Endothelial Progenitor Cell StudyEnd Stage Renal DiseaseNCT00182559Medical University of Vienna148
Terminated
Not Applicable
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic MalignancyInvasive Fungal InfectionNCT01148160Asan Medical Center10
Completed
Not Applicable
Empirical Antibiotic and Outcome in Community-onset BacteremiaBacteremiaNCT03765749Phramongkutklao College of Medicine and Hospital108